New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NVO;VPHM;INFI;MRK;AGN;SHPG;SGEN;OREX;AMGN;SNY;JNJ;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 >>
August 27, 2015
17:58 EDTAMGNEsperion up 1.9% after FDA approves Amgen cholesterol drug Repatha
Subscribe for More Information
17:55 EDTAMGNAmgen confirms FDA approval of Repatha cholesterol-lowering medication
Subscribe for More Information
17:38 EDTPFES&P announces changes to S&P 500 index
Subscribe for More Information
17:24 EDTAMGNFDA approves Repatha
The U.S. Food and Drug Administration approved Repatha injection for some patients who are unable to get their low-density lipoprotein cholesterol under control with current treatment options. Repatha is marketed by Amgen Inc., of Thousand Oaks, Calif. Reference Link
08:06 EDTAMGNFDA PDUFA Date for Amgen's Repatha is August 27, 2015
07:24 EDTPFEPfizer shares even more compelling after recent weakness, says Piper Jaffray
Subscribe for More Information
06:55 EDTPFEHospira sees merger closing on or about September 3
Hospira (HSP) said in a regulatory filing that on August 21, Hospira and Pfizer (PFE) received clearance from the U.S. FTC, relating to the pending merger of Hospira with Perkins Holding Company, a wholly-owned subsidiary of Pfizer. All required regulatory approvals have now been secured, though the merger remains conditioned upon the expiration of a post-clearance waiting period in one foreign jurisdiction. Hospira expects the merger to close on or about September 3.
August 26, 2015
08:53 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
07:32 EDTPFEPfizer launches Phase 3 trial of targeted therapy for breast cancer patients
Subscribe for More Information
06:16 EDTPFEAlvogen to acquire product portfolio from Pfizer for US market
Subscribe for More Information
06:02 EDTAMGNAmgen implied volatility of 41 at upper end of index
August 25, 2015
16:43 EDTSHPGOn The Fly: Top stock stories for Tuesday
Subscribe for More Information
14:16 EDTPFEMylan launches generic version of Pfizer's Zosyn Injection
Mylan (MYL) announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's (PFE) Zosyn Injection. This product is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria. Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials had U.S. sales of approximately $72.1M for the 12 months ending June 30, 2015, according to IMS Health. Mylan's launch of this product adds to the company's growing portfolio of more than 145 injectable products available to patients in the U.S. across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
13:01 EDTJNJJ&J unit to sell Splenda brand to Heartland Food, terms not disclosed
Subscribe for More Information
09:16 EDTAMGNAmgen to present Repatha data analysis at ESC Congress 2015
Subscribe for More Information
09:03 EDTSHPG, JNJAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
09:02 EDTAMGNAmgen submits NDA for hyperparathyroidism treatment
Subscribe for More Information
08:14 EDTAGNAllergan multiple is low, says Leerink
Leerink predicts that Allergan's 2016 EPS will come in at $17-$18. The firm thinks the company has "durable revenue streams," and a "deep pipeline with several potential blockbuster candidates." Leerink adds that the company "has significant capacity for M&A." It keeps a $388 price target and Outperform rating on the shares.
07:06 EDTSHPGShire reaches CINRYZE agreement with Sanquin Blood Supply
Subscribe for More Information
06:18 EDTJNJSears names Lynn Pendergrass as Hardlines president
Subscribe for More Information
<< 1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use